Detalhe da pesquisa
1.
Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.
J Biol Chem
; 289(9): 5820-7, 2014 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24403076
2.
The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
Blood
; 122(22): 3628-31, 2013 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24081659
3.
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
Blood
; 118(24): 6392-8, 2011 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-21860020
4.
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Sci Signal
; 11(539)2018 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30018082
5.
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.
J Hematol Oncol
; 10(1): 173, 2017 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29132397
6.
JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model.
Exp Hematol
; 44(1): 24-9.e1, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26458983
7.
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Clin Cancer Res
; 22(3): 757-64, 2016 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26475333
8.
Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.
Cancer Res
; 76(1): 127-38, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26677978
9.
Therapeutically Targetable ALK Mutations in Leukemia.
Cancer Res
; 75(11): 2146-50, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26032424